IQVIA Holdings Inc. (IQV) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

IQVIA Holdings Inc. (IQV) Healthcare & Pipeline Overview

IQVIA Holdings Inc. (IQV) is a global leader providing advanced analytics, technology solutions, and clinical research services to the life sciences industry. With a comprehensive suite of offerings spanning from cloud-based applications to clinical trial support, IQVIA serves pharmaceutical, biotechnology, and healthcare companies across the Americas, Europe, and Asia-Pacific.

What Is the Investment Thesis for IQV?

With a market capitalization of $43.1B and a P/E ratio of 31.65, IQVIA demonstrates solid financial performance. The company's diverse service offerings, spanning technology, analytics, and clinical research, provide multiple revenue streams and reduce reliance on any single market segment. Key growth catalysts include the increasing demand for data-driven healthcare solutions and the expansion of clinical trials globally. A potential risk lies in the competitive landscape, with companies like Agilent Technologies, Inc. and Cardinal Health, Inc. vying for market share. However, IQVIA's established presence and comprehensive service portfolio position it favorably for sustained growth.

Based on FMP financials and quantitative analysis

IQV Key Highlights

IQVIA operates in three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions, offering diverse revenue streams.

• The company serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies, indicating a broad customer base.
• IQVIA's strategic collaboration with HealthCore, Inc. enhances its capabilities in evidence generation for healthcare decision-making.
• With a profit margin of 8.3% and a gross margin of 26.1%, IQVIA demonstrates solid financial performance.
• IQVIA's beta of 1.39 suggests higher volatility compared to the market, potentially offering higher returns but also increased risk.

Who Are IQV's Competitors?

IQV is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are IQV's Key Strengths?

Comprehensive service offerings across technology, analytics, and clinical research.

• Global presence and established relationships with key industry players.
• Strong data analytics capabilities and proprietary data assets.
• Experienced management team and strategic collaborations.

What Are IQV's Weaknesses?

Reliance on the life sciences industry, making it susceptible to industry downturns.

• Exposure to regulatory changes and compliance requirements.
• Potential for data breaches and security risks.
• Competition from specialized service providers.

What Could Drive IQV Stock Higher?

Increasing demand for data-driven healthcare solutions and real-world evidence.

• Expansion of clinical trials globally and the need for efficient research and development services.
• Strategic partnerships and collaborations to expand service offerings and geographic reach.
• Potential acquisitions of complementary businesses to enhance capabilities.
• Development of new technologies and services to address evolving client needs.

What Are the Key Risks for IQV?

Rich valuation — a P/E of 31.65 runs well above the Healthcare sector’s ~21.50x, leaving little room for a miss.

• Insider selling — insiders were net sellers of roughly $30.6M recently.
• Economic downturns and reduced healthcare spending could negatively impact demand for IQVIA's services.
• Changes in government regulations and healthcare policies could create uncertainty and affect the company's business.
• Intense competition from established and emerging players could erode market share and pricing power.
• Data breaches and security risks could damage the company's reputation and result in financial losses.
• Reliance on the life sciences industry makes IQVIA susceptible to industry-specific risks and challenges.

What Are the Growth Opportunities for IQV?

• Growth opportunity 1: Expansion of Real-World Evidence (RWE) Solutions: IQVIA can capitalize on the increasing demand for RWE in healthcare decision-making. The RWE market is projected to reach $2.5 billion by 2027, driven by the need for data-driven insights to improve patient outcomes and reduce healthcare costs. IQVIA's real-world solutions enable life sciences and provider customers to generate and disseminate evidence, positioning the company to capture a significant share of this growing market. Timeline: Ongoing.
• Growth opportunity 2: Leveraging Cloud-Based Technology: IQVIA's Technology & Analytics Solutions segment can drive growth by expanding its cloud-based applications and related implementation services. The global healthcare cloud computing market is expected to reach $55.6 billion by 2027, fueled by the need for scalable and secure data management solutions. IQVIA's cloud offerings provide clients with advanced analytics and commercial processes outsourcing services, creating a competitive advantage. Timeline: Ongoing.
• Growth opportunity 3: Strategic Partnerships and Collaborations: IQVIA can pursue strategic partnerships and collaborations to expand its service offerings and geographic reach. The company's existing collaboration with HealthCore, Inc. demonstrates the potential for synergistic relationships. By partnering with other healthcare providers, technology companies, and research institutions, IQVIA can enhance its capabilities and access new markets. Timeline: Ongoing.
• Growth opportunity 4: Growth in Emerging Markets: IQVIA can expand its presence in emerging markets, where the demand for healthcare services is rapidly increasing. The healthcare market in Asia-Pacific is projected to grow at a CAGR of 7.8% from 2021 to 2026, driven by rising incomes and increasing access to healthcare. By establishing a stronger presence in these markets, IQVIA can tap into new revenue streams and diversify its geographic footprint. Timeline: Ongoing.
• Growth opportunity 5: Advancements in Virtual Trials: IQVIA can further develop its virtual trials capabilities to capitalize on the growing trend towards remote clinical research. IQVIA's virtual trials services offer project management, clinical monitoring, and strategic planning, positioning the company to capture a significant share of this expanding market. Timeline: Ongoing.

What Are IQV's Competitive Advantages?

• Proprietary Data Assets: IQVIA possesses a vast collection of healthcare data, providing a competitive advantage in analytics and insights.
• Global Scale and Reach: The company operates in numerous countries, enabling it to serve clients worldwide.
• Comprehensive Service Portfolio: IQVIA offers a wide range of services, from technology solutions to clinical research, creating a one-stop shop for clients.
• Established Relationships: IQVIA has long-standing relationships with pharmaceutical, biotechnology, and healthcare companies.

What Does IQV Do?

Founded in 1982 and headquartered in Durham, North Carolina, IQVIA Holdings Inc. has evolved into a pivotal player in the life sciences sector. Originally known as Quintiles IMS Holdings, Inc., the company rebranded to IQVIA in November 2017, marking a shift towards its focus on data-driven insights and technology-enabled solutions. IQVIA operates through three primary segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers cloud-based applications, real-world solutions, and strategic consulting services, providing clients with country-level performance metrics and advanced analytics. The Research & Development Solutions segment delivers project management, clinical monitoring, and laboratory services, supporting clinical trials and research initiatives. The Contract Sales & Medical Solutions segment focuses on healthcare provider and patient engagement, offering scientific strategy and medical affairs services. IQVIA serves a diverse clientele, including pharmaceutical, biotechnology, device and diagnostic, and consumer health companies across the Americas, Europe, Africa, and the Asia-Pacific regions. The company's strategic collaboration with HealthCore, Inc. further enhances its capabilities in generating and disseminating evidence to improve healthcare decision-making and patient outcomes.

What Products and Services Does IQV Offer?

• Provides advanced analytics to the life sciences industry.
• Offers technology solutions, including cloud-based applications.
• Delivers clinical research services, supporting clinical trials.
• Provides real-world solutions for evidence generation and dissemination.
• Offers strategic and implementation consulting services.
• Provides healthcare provider and patient engagement services.
• Offers scientific strategy and medical affairs services.

How Does IQV Make Money?

• Generates revenue through Technology & Analytics Solutions, offering cloud-based applications and consulting services.
• Earns revenue from Research & Development Solutions, providing project management and clinical monitoring for clinical trials.
• Derives revenue from Contract Sales & Medical Solutions, offering healthcare provider and patient engagement services.
• Serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies.

What Industry Does IQV Operate In?

IQVIA operates within the medical diagnostics and research industry, a segment experiencing significant growth driven by advancements in technology and increasing healthcare expenditures. The global market for clinical trial services is projected to reach $83 billion by 2027, reflecting the growing demand for research and development in the life sciences sector. IQVIA competes with companies like Cardinal Health, Inc. and Agilent Technologies, Inc., each offering specialized services within the healthcare ecosystem. IQVIA's comprehensive suite of solutions and global reach position it as a key player in this competitive landscape, enabling it to capitalize on the industry's growth trends.

Who Are IQV's Key Customers?

• Pharmaceutical companies seeking clinical trial support and data analytics.
• Biotechnology companies requiring research and development solutions.
• Device and diagnostic companies needing market insights and strategic consulting.
• Consumer health companies looking to engage healthcare providers and patients.

Company Profile

IQVIA Holdings Inc. operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Durham, US. The company is led by CEO Ari Bousbib. IQV has traded publicly since 2013.

IQVIA Holdings Inc. Financial Trajectory

IQVIA Holdings Inc. (IQV) reported $4.37B in revenue for Q2 FY2026, reflecting 5.2% growth compared to the prior quarter. The company recorded net income of $256.0M, with diluted EPS of $1.52. Quarter-over-quarter revenue has been mixed, typical for a large-cap company operating in Healthcare. Across the four most recent quarters, IQV averaged $2.01 in diluted EPS.

How IQVIA Holdings Inc. Is Valued

IQVIA Holdings Inc. carries a market capitalization of $43.1B, placing it in the large-cap category. Analyst price targets span from $185.00 to $287.00, with a consensus of $237.38. At the current price of $261.88, that implies roughly 9% downside from the consensus target. Relative to its peer group, IQV's quantitative score of 72/100 is roughly in line with the peer average of 73/100.

Return on equity for IQVIA Holdings Inc. stands at 22.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 4.7%, showing how much profit it generates from its asset base. IQV trades at a trailing price-to-earnings ratio of 31.65, above the Healthcare sector average of ~21.50x. Its free cash flow yield is 7.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.75 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 4.3%, the inverse of the P/E and a quick read on earnings relative to price.

IQVIA Holdings Inc.'s Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 2.16 places it in the grey zone, a middle ground that warrants monitoring.

IQVIA Holdings Inc. has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 1.6% above estimates on average.

Over the past six months, IQVIA Holdings Inc. insiders filed 15 SEC Form 4 transactions — 13 sales and 2 purchases. On net that is roughly 18K shares disposed (about $30.6M), a signal worth weighing alongside the fundamentals.

IQV Financials

Next earnings report: Nov 3, 2026

IQV Latest News

IQV Analyst Consensus

IQV MoonshotScore

Latest IQVIA Holdings Inc. Analysis

Common Questions About IQV (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources